Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.

doi:10.1016/J.BMCL.2004.09.053

Paper

Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.

Published Dec 20, 2004 · Carlos Jaramillo, J. D. de Diego, C. Hamdouchi

Bioorganic & medicinal chemistry letters

Q2 SJR score

31

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Aminoimidazo[1,2-a]pyridines show potential as a new class of ATP-site directed protein kinase inhibitors, offering a new tool for treating cancer and other diseases involving protein kinase signaling pathways.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.

References

Citations